Prothena Corporation plc
PRTA
Market Cap$457.53M
Close$
$35.32
397.5% upside
Current Fair Value
397.5% upsideUndervalued by 397.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $457.53 Million |
|---|---|
| Enterprise Value | $5.83 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.27 |
| Beta | 0.07 |
| Outstanding Shares | 53,815,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.74 |
|---|---|
| PEG | 1.01 |
| Price to Sales | 3.55 |
| Price to Book Ratio | 0.79 |
| Enterprise Value to Revenue | 0.04 |
| Enterprise Value to EBIT | -0.04 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 3.38 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Prothena Corporation plc
7 employees
CEO: Gene Kinney Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...